Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P00441: Variant p.Asp102Gly

Superoxide dismutase [Cu-Zn]
Gene: SOD1
Feedback?
Variant information Variant position: help 102 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Aspartate (D) to Glycine (G) at position 102 (D102G, p.Asp102Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (D) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In ALS1. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 102 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 154 The length of the canonical sequence.
Location on the sequence: help VGDLGNVTADKDGVADVSIE D SVISLSGDHCIIGRTLVVHE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 154 Superoxide dismutase [Cu-Zn]
Binding site 84 – 84
Binding site 121 – 121
Modified residue 92 – 92 N6-succinyllysine
Modified residue 99 – 99 Phosphoserine
Modified residue 103 – 103 Phosphoserine
Modified residue 106 – 106 Phosphoserine
Modified residue 108 – 108 Phosphoserine
Disulfide bond 58 – 147
Mutagenesis 84 – 84 D -> A. Loss of zinc binding and enhanced tendency to form aggregates; when associated with A-81.
Mutagenesis 84 – 84 D -> S. Destabilization of dimer and loss of zinc binding; when associated with S-81.
Mutagenesis 112 – 112 C -> S. Enhances formation of fibrillar aggregates in the absence of bound zinc; when associated with S-7; S-58 and S-147.
Beta strand 96 – 104



Literature citations
An improved protocol for the analysis of SOD1 gene mutations, and a new mutation in exon 4.
Yulug I.G.; Katsanis N.; de Belleroche J.; Collinge J.; Fisher E.M.C.;
Hum. Mol. Genet. 4:1101-1104(1995)
Cited for: VARIANT ALS1 GLY-102; Screening of SOD1, FUS and TARDBP genes in patients with amyotrophic lateral sclerosis in central-southern China.
Hou L.; Jiao B.; Xiao T.; Zhou L.; Zhou Z.; Du J.; Yan X.; Wang J.; Tang B.; Shen L.;
Sci. Rep. 6:32478-32478(2016)
Cited for: VARIANTS ALS1 SER-87; ALA-88; ASN-102; GLY-102 AND TYR-112;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.